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Carcinoma-associated fibroblasts (CAFs) promote
tumor invasion by secreting soluble factors. A tagged
triazine library was screened in our novel transwell
coculture model of CAF and oral squamous cell
carcinoma (OSCC). We discovered compound S06,
which reduced OSCC invasion by inhibiting secre-
tion of CAF-derived proinvasive chemokines. The
N-terminus of Hsp90 was found to be the cellular
target of S06. Importantly, S06 did not induce hepatic
toxicity, a side effect associated with well-known
Hsp90 inhibitors. Moreover, S06 inhibited tumor cell
migration in a zebrafish xenograft model. Our results
demonstrate that Hsp90 is a novel target for stromal-
based therapy to modulate proinvasive molecular
crosstalk within the tumor microenvironment. Fur-
thermore, S06 represents a new class of Hsp90 inhib-
itor and is an attractive candidate for anticancer drug
development.
INTRODUCTION
Forward chemical genetics uses chemical libraries to identify
phenotypic changes and target specific proteins (Schreiber,
1998). Small molecules replace the mutation-inducing agents
(e.g., DNA adducts and X-ray irradiation) used in classical
genetics. Nonetheless, the promise of chemical genetics is
restricted by experimental difficulties associated with target
identification, such as conjugating the active lead compound
to an affinity matrix without reducing biological activity. To over-
come this problem, chemically tagged small-molecule libraries
have been developed that possess a built-in linker (Kim and
Chang, 2007). The presence of a linker in the chemical libraryChemistry & Biology 18, 1581–159prior to biological screening reduces the need for laborious
structure-activity relationship studies.
Forward chemical genetics has been used in cancer research
to discover new drugs and novel drug targets (Nakai et al.,
2006; Williams et al., 2008). In the past decade, cancer research
has increasingly focused on the tumor microenvironment as
a key regulator of carcinoma progression (Bissell and Hines,
2011; Kolata, 2009; Langley and Fidler, 2011). The tumor micro-
environment is a complex milieu consisting of various cell
types, extracellular matrix macromolecules, and cell signaling
molecules. Among them, carcinoma-associated fibroblasts
(CAFs) have been recognized as prominent modifiers of tumor
initiation and progression (Kalluri and Zeisberg, 2006). CAFs
communicate with other types of cells including cancer cells,
playing an active role in carcinogenesis by increasing tumor
cell growth, angiogenesis, and invasiveness through secretion
of chemokines (Jung et al., 2010; Orimo et al., 2005). This mole-
cule-based communication is termed ‘‘crosstalk’’ (Condon,
2005). Therefore, the molecular crosstalk between cancer cells
and CAFs has emerged as a potential target for new drug
development.
Recently, we have shown that the chemokine (C-C motif)
ligand 7 (CCL7) is a key modulator of the proinvasive crosstalk
between CAFs and oral squamous cell carcinoma (OSCC)
(Jung et al., 2010). As a next approach, the current study at-
tempted to discover novel inhibitors of CAF crosstalk with carci-
noma cells by a forward chemical approach. We chose to study
OSCC in our model, because it comprises over 90% of human
head and neck cancers (Vokes et al., 1993) and because it is
relatively easy to obtain sufficient numbers of biopsy specimens
for primary cell culture. A collagen-insert-based transwell
culture system was used to screen a tagged triazine library of
small molecules for modulators of the cytokine-based crosstalk
between CAFs and carcinoma. Using this approach, we
identified a novel triazine compound, S06, as an inhibitor of
carcinoma-CAF crosstalk, targeting the molecular chaperone
heat-shock protein 90 (Hsp90).0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1581
Figure 1. Novel Triazine S06 Inhibits OSCC Cell Invasion Induced by CAF
(A) Screening system used to identify novel regulators of cancer cell invasion. A tagged chemical library of 1040 benzoyl-capped triazines was used for screening.
Five mMof each triazine compound was added to the lower chamber of a transwell-based cell-culture system containing YD10BOSCC cells and CAFs separated
by an 8-mm porous collagen-coated insert. After 48 hr incubation, the inserts were removed and stained with crystal violet to quantify YD10B invasion.
(B) Chemical structure of S06.
(Ci) Crystal violet staining of YD10B cells invaded onto the transwell inserts. Treatment with increasing concentrations of S06 for 48 hr reduced YD10B invasion in
a dose-dependent manner. Scale bar = 200 mM.
(Cii) Quantification of the inhibitory effect of S06 on YD10B invasion. #p < 0.01 compared to control. Cell viability of CAFs cocultured in the system was measured
using MTT assay after the S06 treatment.
(Ciii) S06 treatment reduced YD10B cell viability in a dose-dependent manner in the coculture system. CAFs and YD10B cells were cultured in the upper and lower
chambers, respectively, of 24-transwell plates containing collagen-coated 1-mm-pore transmembrane filters. S06 (5, 10, and 25 mM) was added to the coculture
and cell viability was assessed by MTT assay after 48 hr incubation. *p < 0.05 compared to control; #p < 0.01 compared to control.
Data in Figures Ci–Ciii are representative of three independent experiments (mean ± SD of triplicate assays). DMSO served as a control. See also Figure S1.
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Identification of a Triazine Compound, S06, as a Novel
Inhibitor of OSCC Invasion Induced by CAFs
In our previous study (Jung et al., 2010), we found that CAFs
greatly increase OSCC cell invasion in a transwell-based cocul-
ture system by secreting proinvasive and promigratory signals in
response to the cancer cells. To discover novel inhibitors that
inhibit the proinvasive crosstalk between cancer cells and
CAFs, we employed a screening assay based on the 24-trans-
well coculture system. CAFs were added to the bottom chamber
16 hr prior to seeding YD10B OSCC cells. Triazine library
compounds were then added to the transwell at 5 mM (final
concentration) for 48 hr. To rule out the compounds that exhibit
nonspecific toxicity against CAFs, we carried out the MTT assay
using the cocultured CAFs after 48-hr drug treatment.1582 Chemistry & Biology 18, 1581–1590, December 23, 2011 ª2011The chemical structure of the triazine-based small-molecule
library is shown in Figure 1A. Also shown is a diagram of
the screening system used to identify novel modulators of
YD10B OSCC invasion. Screening of this small-molecule library
led to the identification of S06 as a novel inhibitor of YD10B
cell invasion induced by CAFs (Figure 1B).
S06 inhibited YD10B invasion in a dose-dependent manner
without affecting CAF viability (Figures 1Ci and 1Cii). S06 also
reduced YD10B cell viability in the co-culture system (Fig-
ure 1Ciii). However, S06 had a proportionally greater effect on
YD10B invasion compared to viability. For example, S06
reduced YD10B cell invasion by 44 ± 2% at the 5 mM concentra-
tion at which YD10B cell viability (85 ± 2%) showed only a slight
reduction (shown in Figures 1Cii and 1Ciii), indicating that the
anti-invasive effect of S06 was resulted from modulating proin-
vasive signals from CAFs rather than inhibiting cancer cellElsevier Ltd All rights reserved
Figure 2. S06 Decreases the Secretion of
Proinvasive Chemokines by CAF
(Ai and Aii) Cytokine array analysis showed that
5 mM S06 treatment of CAFs for 24 hr reduced the
expression of proinvasive cytokines MCP-2/CCL8
(box 2), MCP-3/CCL7 (box 3), MCSF (box 4), and
SCF (box 5). However, expression of the proinva-
sive cytokine IL-8/CXCL8 (indicated by box 1) re-
mained unchanged. Data shown are representa-
tive of two independent experiments. See also
Figure S2.
(Bi and Bii) CAFs (23 104 cells/well) were cultured
with YD10B (2 3 104 cells/well) in the presence
and absence of S06 (1, 2.5, and 5 mM) for 24 hr in
24-transwell plates. DMSO served as a control.
Data are representative of three independent
experiments (mean ± SD of triplicate assays). (Bi)
ELISA confirmed that treatment with S06 for 24 hr
reduced the secretion of CCL7 by CAFs. Treat-
ment with S06 had no significant effect on CAF
viability. (Bii) ELISA confirmed that treatment with
S06 for 24 hr had no significant effect on CXCL8
secretion byCAFs, which is in accordance with the
cytokine antibody array data shown in Figure 2A.
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invasion by perturbing proinvasive properties of CAFs, in addi-
tion to inhibiting cancer cell proliferation. Furthermore, S06
exhibited anti-invasive effects on other OSCC cell lines (HSC-2
and Ca9.22) in a dose-dependent manner (Figure S1 available
online).
S06 Reduced the Secretion of Proinvasive Chemokines
by CAFs
To determine the effect of S06 on cytokine secretion by CAF,
cytokine antibody array analysis was performed using CAF-
conditioned media, treated with or without 5 mM S06. We found
that S06 inhibited the secretion of proinvasive and pro-migratory
chemokines, such as chemokine (C-C motif) ligand 7 (CCL7/
MCP-3) and chemokine (C-C motif) ligand 8 (CCL8/MCP-2)
(Figures 2Ai, 2Aii, and S2). In addition, macrophage colony stim-
ulating factor (MCSF), and stem cell factor (SCF), known as
cancer-promoting cytokines (Filderman et al., 1992; Huang
et al., 2008) also showed decreased secretion in response to
treatment with S06. Recently, CCL7 has been shown to be
a key mediator of OSCC invasion (Jung et al., 2010). Enzyme-
linked immunosorbent assay (ELISA) confirmed that S06 also in-
hibited the secretion of CCL7 by CAFs stimulated with YD10B
culture, without affecting CAF cell viability (Figure 2Bi). In addi-Chemistry & Biology 18, 1581–1590, December 23, 2011 ªtion, ELISA confirmed that S06 had no
effect on the secretion of CXCL8 by
CAFs stimulated with YD10B culture (Fig-
ure 2Bii), which is also in accordance with
the result obtained from the cytokine anti-
body array.
S06 Targets Hsp90 in Both OSCC
Cells and CAFs
Affinity chromatography using an S06-
conjugated matrix showed that Hsp90aand tubulin were the specific targets in YD10B OSCC cells
(Figure 3Ai). However, S06 did not affect tubulin polymerization
(Figure S3A), indicating that tubulin is not an active target. The
Hsp90a peptide fragments identified by mass spectrometry
are shown in Figure 3Aii. Competition binding studies using
free S06-A (without the linker portion, structure and activity
shown in Figure S3B) confirmed that S06 binds to Hsp90a
and TNF receptor-associated protein 1 (TRAP-1, a 75-kD
paralog of Hsp90a containing a conserved N-terminus) in
YD10B cells (Figure 3B). An identical result was found in CAF
(Figure 3C). In support of this result, an S06-conjugated matrix
could also bind to recombinant Hsp90a (Figures 3Di and 3Dii).
It was found that S06 binds to the N-terminus of Hsp90a in
a dose-dependent manner (Figures 3Ei and S3D). Binding of
the S06-conjugated matrix to the Hsp90a N-terminus was
confirmed by competition binding analysis using free S06-A
and S06 (Figures 3Eii and S3E).
Inhibition of Hsp90 in CAF Decreased CCL7 Secretion
and Reduced Cancer Cell Invasion
To validate Hsp90 as a cellular target of S06 in CAFs, we carried
out knockdown of Hsp90 expression in CAFs using siRNA.
Western blotting was used to confirm Hsp90 knockdown
by siRNA (64% expression compared to control; Figure 4Ai).2011 Elsevier Ltd All rights reserved 1583
Figure 3. Affinity Pull Down Assays Identi-
fied Hsp90 as a Target of S06
(Ai) Drug target study for the S06 in YD10B
cell lysate. Eluted proteins were separated by
10% SDS-PAGE. Lanes: competitor, conjugated
affinity matrix in the presence of 100 mM S06-A;
control, conjugated affinity matrix in the absence
of S06-A. S06-A is a derivative of S06 with the
linker moiety removed.
(Aii) Hsp90a proteins identified by MALDI TOF
MS/MS analysis.
(B) Competition studies for the S06 in YD10B cell
lysate. Eluted proteins were blotted and probed
with antibodies against Hsp90a and TNF receptor-
associated protein 1 (TRAP-1, a 75 kD paralog
of Hsp90a containing a conserved N-terminus).
Lanes: competitor, conjugated affinity matrix in
the presence of 100 mM S06-A; control, conju-
gated affinity matrix in the absence of S06-A.
(C) Competition binding studies for the S06 in CAF
cell lysate. Eluted proteins were blotted and pro-
bed with antibodies against Hsp90a and TRAP-1.
Lanes, Competitor, conjugated affinity matrix in
the presence of 100 mM S06-A; control, conju-
gated affinity matrix in the absence of S06-A.
(D) S06 affinity matrix binds to full-length human
recombinant Hsp90a tagged with histidine.
(Di) Eluted proteins were separated on a 10%
SDS-PAGE gel, blotted, and probed with an
antihistidine antibody. Lanes: NG, inactive
compound N10-conjugated affinity matrix (chem-
ical structure of N10 is shown in Figure S3F).
S06, S06-conjugated affinity matrix.
(Dii) Silver staining. Eluted proteins were sepa-
rated on a 10% SDS-PAGE gel.
(Ei) S06-conjugated affinity matrix was incubated with histidine-tagged N-terminal (amino acids 12–230) or C-terminal (amino acids 539–732) fragments of human
Hsp90a. After washing, the eluate was blotted and probed with the histidine-specific monoclonal antibody.
(Eii) Competitive binding of S06 to the N-terminal fragment. S06-conjugated affinity matrix was incubated with histidine-tagged N-terminal fragment with or
without S06-A (50 and 100 mM). The eluate was blotted and probed with the antihistidine antibody. NG-conjugated, inactive compound N10-conjugated affinity
matrix. See also Figure S3.
Chemistry & Biology
An Hsp90 Inhibitor Blocks Tumor-Stromal CrosstalkHsp90 knockdown in CAFs reduced invasion of cocultured
OSCC cells (56 ± 9% of control cell invasion) and secretion of
the key proinvasive chemokine CCL7 (67 ± 2.4% compared to
control; shown in Figures 4Aii and 4Aiii).
In addition, 17-AAG, a widely-characterized Hsp90 inhibitor,
was shown to decrease CCL7 secretion in either CAF mono-
culture or co-cultured CAFwith OSCC cells, inhibiting the cancer
cell invasion (Figures 4B and 4C).
Furthermore, Hsp90 inhibition by S06 or 17-AAG treatment
was found to inhibit nuclear-factor kappa-light-chain-enhancer
of activated B cell (NFkB) activation in CAFs (Figure S4),
providing an explanation for the relationship between Hsp90
inhibition and the CCL7 decrease, which are known to be induc-
ible through the NFkB pathway (Thompson and Van Eldik, 2009).
S06 Exhibited Less Toxicity against Hepatocytes
Compared to 17-AAG
Antibiotic derivative 17-AAG is a widely characterized Hsp90
inhibitor that is in clinical trials for young patients with certain
types of leukemia or solid tumors (Schulte and Neckers, 1998;
Solit et al., 2007). 17-AAG treatment induced cytotoxicity in
YD10B OSCC cells (Figure S5B). However, 17-AAG is also
known to cause hepatotoxicity (Guo et al., 2008), and treatment1584 Chemistry & Biology 18, 1581–1590, December 23, 2011 ª2011of primary C57BL/6 hepatocytes with 5 mM 17-AAG for 48 hr
induced cytoplasm retraction. In contrast, the primary hepato-
cytes treated with the same concentration of S06 appeared
normal (Figure S5A). MTT assay confirmed that S06 treatment
up to 20 mM concentration does not induce hepatotoxicity, in
contrast to 17-AAG, as shown in Figure 5A. IC50 of 17-AAG
was 0.389 mM for 48-hr treatment: only slightly higher (2.6-fold)
than the EC50 for YD10B OSCC cells under the same treatment
(0.148 mM, Figure S5B); however, IC50 of S06 was 65.4 mM: 13.3-
fold higher than the EC50 for YD10B OSCC cells (4.9 mM,
Figure S5C).
S06 Inhibits OSCC Cell Migration and Metastasis In Vivo
Zebrafish (Danio rerio) is gaining increasing research promi-
nence as a model for measuring cancer cell progression (Liu
and Leach, 2011; Rouhi et al., 2010). DiI-labeled OSCC cells
were injected into the zebrafish yolk sac at 48 hpf (Figure S5D)
and treated with 5 mM S06, 150 nM 17-AAG, or 50 nM paclitaxel
in 96-well plates. The concentrations 5 mM S06 and 150 nM
17-AAG were chosen for this study because they showed no
toxicity in the hepatocyte culture, as shown in Figure 5A. Pacli-
taxel served as a positive control. Four days later, embryos
treated with 5 mM S06 showed reduced OSCC cell migrationElsevier Ltd All rights reserved
Figure 4. Inhibition of Hsp90 Decreased
CCL7 Secretion and Reduced Cancer Cell
Invasion in Co-Culture System
(A) Effect of Hsp90 gene knockdown in CAFs on
CCL7 secretion and induction of cancer cell inva-
sion. CAFs were treated with Hsp90 siRNA for
48 hr and then cocultured with YD10B cancer cells
in the transwell system for 24 hr. Data are repre-
sentative of three independent experiments
(mean ± SD of triplicate assays).
(Ai) Immunoblotting to confirm that treatment of
CAFs with Hsp90 siRNA for 48 hr reduced the
expression of Hsp90. Numbers beneath each blot
show the fold change in band intensity; actin was
used as a loading control for normalization.
(Aii) Gene knockdown of Hsp90 in CAFs reduced
the invasion of cocultured YD10B cells. (Aiii) Gene
knockdown of Hsp90 in CAFs reduced the
secretion of CCL7 by CAFs.
(Bi and Bii) Comparison of CCL7 secretion by
CAFs after treatment with S06 (i) or the widely
studied anticancer drug 17-AAG (ii), which also
targets Hsp90. CAFs were treated with drug for
48 hr. #p < 0.01 compared to untreated cells. Data
are representative of three independent experi-
ments (mean ± SD of triplicate assays). DMSO
served as a control.
(C) 17-AAG treatment reduced CCL7 release from
CAFs increased by cocultured OSCC cells and
decreased OSCC cell invasion toward cocultured
CAFs. 17-AAG at two concentrations, 75 nM and
150 nM, was treated in the transwell-based CAF-
YD10B coculture. Data are representative of three
independent experiments (mean ± SD of triplicate
assays). DMSO served as a control. See also
Figure S4.
(Ci) At 24 hr after treatment, YD10B cell invasion
was measured by counting transmigrated cells
through transwell filters.
(Cii) The culture media were collected for CCL7-
specific ELISAs.
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An Hsp90 Inhibitor Blocks Tumor-Stromal Crosstalkand metastasis from the injection site (Figure 5B). Of the xeno-
planted fish, 48 ± 6% showed cell migration and metastasis
after S06 treatment, whereas 63 ± 3% showed cell migration
and metastasis in the untreated control group. A similar
reduction in numbers of xenoplanted fish (38 ± 8%) showed
cell migration and metastasis in zebrafish treated with 50 nM
paclitaxel (a tubulin stabilizing drug used in cancer chemo-
therapy [Wani et al., 1971]). However, 17-AAG was found to be
less effective than S06 (54 ± 4%). Representative OSCC-cell
xenoplanted fish and S06-treated xenoplanted fish are shown
in Figure 5Bii.
DISCUSSION
The tumor microenvironment is a major focus for understanding
cancer progression (Guise, 2010; Witz, 2008). However, there
is no previous published report exploiting new drugs targeting
the molecular crosstalk in this microenvironment. To our
knowledge, in the present study, we discovered, for the first
time, a key regulator of tumor-fibroblast crosstalk in themicroen-
vironment via a forward chemical genetic approach. Moreover,Chemistry & Biology 18, 1581–159we also present S06 as a novel class of Hsp90 inhibitor that
possesses therapeutic potential for drug development, based
on low hepatotoxicity and promising animal model data.
The transwell cell culture system used in our study is well
suited for identifying newmodulators of the tumor microenviron-
ment. CAFs, recognized as a main cell type of the tumor stroma,
were cocultured with cancer cells to induce cancer cell invasion.
Collagen-type-I-coated porous membrane separated the
two types of cells, allowing proinvasive crosstalk mediated
by soluble factors, rather than direct cell-cell contact. The
compound of interest can be added to the culture media while
the cell populations remain physically separated by the collagen
matrix and porous membrane insert. Cancer cell invasion can be
simply measured by staining cells that are retained by the
membrane. To rule out compounds that exhibit nonspecific cyto-
toxicity, CAFs can be tested for viability after drug treatment. For
screening, the linker-tagged benzoyl-capped small-molecule
library of triazines was chosen because of previous successes
using this library, such as the dissection of cellular pathways
relating to pigmentation and insulin signaling (Min et al., 2007;
Williams et al., 2004). Our screening system is also suitable for0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1585
Figure 5. S06 Inhibits OSCCCell Metastasis
In Vivo
(A) MTT assay analysis showed that treatment with
novel Hsp90 inhibitor S06 did not adversely affect
hepatocyte viability. In contrast, hepatocytes
treated with the known Hsp90 inhibitor 17-AAG
showed a significant reduction in viability 48 hr
after AAG treatment. Data shown are representa-
tive of three independent experiments (mean ± SD
of triplicate assays). DMSO served as a control.
(Bi) Treatment of YD10B-xenotransplanted ze-
brafish with S06, 17-AAG, or paclitaxel for 96 hr
reduced the number of embryos showing migra-
tion and metastasis (distributed cancer cells).
Error bars indicate the mean ± SD; *p < 0.05
compared to control; #p < 0.01 compared to
control fish; data are the mean of three indepen-
dent experiments. DMSO served as a control.
(Bii) Three representative embryos are shown for
each treatment group. Microtumor foci are
designated by arrows. See also Figure S5.
Chemistry & Biology
An Hsp90 Inhibitor Blocks Tumor-Stromal Crosstalkfurther optimization, such as colorimetric assessment of tumor
cell invasion (Saito et al., 1997).
The tumor microenvironment exerts its influence on cancer
progression through an extremely complex network of cyto-
kines, chemokines, and extracellular matrix components
(Kalluri and Zeisberg, 2006). Thus, it is especially important to
identify key regulators within this environment. An earlier report
from our group described the chemokine CCL7 as a pivotal
component of the carcinoma microenvironment (Jung et al.,
2010). Cytokine antibody array analysis showed that S06
produced a fairly specific effect on the stromal fibroblast-
carcinoma cell microenvironment, with just 4 of 44 cytokines
tested being influenced by S06 treatment, one of which was
CCL7 (Figure 2). The other three downregulated cytokines
(CCL8, MCSF, and SCF) have also been shown to be upregu-
lated in the tumor microenvironment and contribute to tumor
invasion (Filderman et al., 1992; Huang et al., 2008; Proost
et al., 1998).
To determine whether S06 inhibits cancer cell proliferation, we
treated S06 to carcinoma cell mono-cultures and carried out cell
viability tests. Induction of cytotoxicity by S06 was studied in
OSCC cell mono-culture, because CAFs have been shown to
enhance cancer cell survival and proliferation (Orimo et al.,
2005). S06 inhibited proliferation in a range of carcinoma cell
lines from different tissues, as well as three different OSCC cell
lines (Figure S6A). In contrast, S06 did not induce cytotoxicity
in primary cultures of human normal epithelial cells (Figure S6A).1586 Chemistry & Biology 18, 1581–1590, December 23, 2011 ª2011 Elsevier Ltd All rights reAnnexin V/carboxyfluorescein diacetate
staining and annexin V/propidium iodide
flow cytometric analysis confirmed that
S06 induces apoptosis in carcinoma cells
(Figures S6B and S6C).
Furthermore, we have shown that the
active cellular target of S06 in both cancer
cell and CAFs is the N-terminus, ATPase-
binding region of Hsp90 (Figure 3; Fig-
ure S3). Hsp90 is a member of a class of
proteins referred to as molecular chaper-ones with key roles in the folding, activation, and assembly of
a range of client proteins. Recently, Hsp90 has received great
attention as an attractive target in cancer therapy due to its crit-
ical role in mediating the maturation and stability of a variety of
cancer-associated proteins (Li et al., 2009; Pearl and Prodro-
mou, 2000; Sharp et al., 2007). However, its role in tumor-asso-
ciated stromal cells, implicating a new paradigm for cancer
therapy through stromal cell inhibition, has not been reported.
In the present study, S06 inhibits tumor invasion by disrupting
the chaperone function of Hsp90 expressed in CAFs, causing
incorrect trafficking of signaling pathway proteins, such as
NFkB, that regulate expression of proinvasive chemokines,
including CCL7 (Qing et al., 2007; Thompson and Van Eldik,
2009). In addition, continuous perturbation of Hsp90 function in
cancer cells eventually produces apoptosis via disruption of
the molecular mechanisms required for their survival. S06 and
17-AAG treatments of OSCC cells reduced the expression of
Hsp90 client proteins that are protective against apoptosis;
Bcl-xL, survivin, and Akt (Figure S6D). It should be noted that
previous studies showed Hsp90 inhibitors can selectively kill
cancer cells compared to normal cells (Kamal et al., 2003). In
addition, a large number of proteins in tumor cells are dependent
upon Hsp90 protein folding machinery for their maturation (Don-
nelly and Blagg, 2008). A schematic of the S06 mode of action is
illustrated in Figure 6.
To our knowledge, our study presented herein is the first use
of forward chemical genetics to discover an Hsp90 inhibitorserved
Figure 6. Schematic Diagram of Tumor Microenvironment Modula-
tion by S06
(A) Oral carcinoma cells activate carcinoma-associated fibroblasts by
secreting cytokines, such as interleukin-1a (Jung et al., 2010). Activated
fibroblasts secrete chemokines, such as CCL7, that promote carcinoma
invasion.
(B) S06 targets the molecular chaperone Hsp90 to block carcinoma pro-
gression. Secretion of proinvasive chemokines from activated fibroblasts is
inhibited by S06 treatment through Hsp90 inhibition. S06 destabilizes anti-
apoptotic Hsp90 client proteins expressed in carcinoma cells, resulting in
programmed cell death of the carcinoma cells. See also Figure S6.
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the tumormicroenvironment. Using this approach, we have been
able to show that S06 perturbs key chemokine signaling
between carcinoma cells and stromal fibroblasts to reduce
carcinoma invasion by inhibiting Hsp90 expressed in the fibro-
blasts. We believe ourmethodology is very useful for discovering
novel anticancer agents, because S06 perturbs molecular
crosstalk within the tumor microenvironment without inducing
significant toxicity in normal cells (Figure S6A). Furthermore,
our study showed that S06 does not induce hepatotoxicity at
a concentration of 20 mM, while OSCC cell viability was
decreased to almost 0%. In contrast, 17-AAG does not induce
hepatotoxicity at 156 nM concentration, but OSCC cell viability
is decreased to only 54% under the same conditions (Figures
5A and S5B). Further comparative studies of S06 and 17-AAG
could include assessment of chaperone function; becauseChemistry & Biology 18, 1581–159a number of proteins upregulated in tumor cells, such as Met,
Akt, and STAT3, are Hsp90 client proteins (McCleese et al.,
2009; Walter and Buchner, 2002). 17-AAG efficacy has been
linked to P-glycoprotein expression and metabolism by NAD(P)
H dehydrogenase (quinone) (Sharp et al., 2007), and it would
be interesting to test whether the function of S06 is also suscep-
tible to these factors.
We have validated the therapeutic potential of S06 in the
zebrafish animal model. Over the past decade, zebrafish have
gained increasing popularity in cancer research (Stern and
Zon, 2003; Taylor and Zon, 2009). This is not only due to
economic and practical considerations; zebrafish also allow
in vivo visualization of cell migration, high-resolution imaging of
transplanted tumor cells, and analysis of interactions between
cancer and host cells. These features are not available in
mammalian models. Incubation of recipient animals with 5 mM
S06 was sufficient to inhibit OSCC cell migration and metastasis
without producing toxic effects in the host. It has been shown
that human tumor cell characteristics, such as relative migration
capabilities, can be replicated in the zebrafish transplantation
model (Haldi et al., 2006; Marques et al., 2009). Thus, based
on the inhibition of migration and metastasis in this animal
model (Figure 5B), S06 is a good candidate for further develop-
ment as an anticancer therapeutic.
Considering the current, intense research effort focused on
dissecting themain regulators of molecular crosstalk, we believe
that our approach provides an excellent methodology for dis-
secting this crosstalk and providing promising therapeutic
agents. Our protocol could be expanded to include other types
of tumor-associated cells, such as tumor-associated macro-
phages and pericytes, or multiple cell populations. Thus, our
approach provides a convenient system for comprehensive
analysis of the tumor microenvironment and identifying novel
drug targets.
SIGNIFICANCE
The tumor microenvironment is now acknowledged as a
key regulator of cancer progression. However, we have not
fully characterized the important signaling pathways that
control tumor cell responses within the microenvironment.
This hampers drug development for blocking cancer metas-
tasis. To our knowledge, our study presents a new approach
to forward chemical genetics: using screening to discover
new molecular targets that control cellular crosstalk in the
tumor microenvironment. To our knowledge, we have
shown for the first time that Hsp90 is an important drug
target for blocking the cellular crosstalk that promotes
tumor invasion. Furthermore, we have shown that our small
molecule inhibitor of Hsp90, termed compound S06, is a
promising new drug candidate for blocking cancer invasion.
Compound S06 shows reduced hepatoxicity compared to
a known Hsp90 inhibitor, 17-AAG, which is currently under-
going clinical evaluation in cancer and leukemia patients.
Moreover, we show that compound S06 is effective at block-
ing tumor cell metastasis in an animal model. Our work is
significant for chemical biology, because we have used
chemical tools to dissect a key regulatory pathway in the
tumor microenvironment. This microenvironment is a milieu0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1587
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fibroblasts, macrophages, and pericytes, in addition to
cancer cells) secreting multiple signaling molecules. Our
approach is important, because we have developed a chem-
ical screen that models a key interaction within this milieu:
tumor cell crosstalk with stromal fibroblasts. Our animal
model data validate our screening system and the discovery
of Hsp90 as a regulator of tumor cell invasion. Thus, we have
shown that forward chemical genetics can be used to
unravel the complex signaling network in the tumor micro-
environment; providing new drug targets and chemical
probes to further our understanding of cancer initiation
and progression.
EXPERIMENTAL PROCEDURES
Antibodies
The following antibodies were purchased from Cell Signaling (Beverly, MA,
USA): cleaved Poly (ADP-ribose) polymerase (PARP), B cell lymphoma-extra
large (Bcl-xL), survivin, and protein kinase B (Akt). Antibodies against cas-
pase-3 were purchased from R&D systems (Minneapolis, MN, USA) and
Cell Signaling. An antibody against Hsp90a was purchased from Abcam
(Cambridge, MA, USA). An antibody against tumor necrosis factor (TNF)
receptor-associated protein 1(TRAP-1) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Antibodies against actin and histidine
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell Culture
CAFs were derived from the surgical specimen of an OSCC patient. Informed
consent for this study was given by the patient to Yonsei University College of
Dentistry, Seoul, Republic of Korea. CAFs were selected by Versene solutions
(0.1 g EDTA and 2 ml glucose in 500 ml PBS) from explanted cancer tissues.
The isolated fibroblasts were characterized by immunohistochemical staining
with anti-vimentin (1:100 dilution, DAKO, Tokyo, Japan) and anti-a-smooth
muscle actin (1:50 dilution, Sigma, St. Louis, MO), along with comparison to
normal fibroblasts, as previously described (Jung et al., 2010). CAFs were
cultured in a 3:1 ratio of Dulbecco’s modified Eagle’s medium (DMEM; GIBCO
BRL, Baltimore, MD, USA) and nutrient mixture F-12 Ham (HAM’s-F12; GIBCO
BRL), supplemented with 10% FBS and 1% penicillin/streptomycin. The
established OSCC cell line YD10B was obtained from the Korean Cell line
Bank (Seoul, Republic of Korea) and cultured as described (Che et al.,
2006). The OSCC cell lines HSC-2 and Ca9.22 were gifts from Professor
T. Muramatsu, Toyko Dental College, Japan, and maintained in DMEM:
Ham’s-F12 (3:1) culture media, supplemented with 10% FBS and 1% peni-
cillin/streptomycin. The breast cancer cell lines MDA-MB-231, MDA-MB-
435, and MCF-7 were obtained from the American Type Culture Collection
(ATCC) and cultured in DMEM supplemented with 10% FBS and 1% peni-
cillin/streptomycin. The PC-3 prostate cancer cell line was maintained in
Ham’s-F12 supplemented with 10% FBS and 1% penicillin/streptomycin.
The A549 lung cancer cell line was maintained in MEM supplemented with
10% FBS and 1% penicillin/streptomycin. The colon cancer cell lines
HT29 and DLD1, and NCI-H460 lung cancer cell lines were maintained in
RPMI1640 supplemented with 10% FBS and 1% penicillin/streptomycin.
PC-3, A549, NCI-H460, HT29, and DLD1were gifts from Professor Sun-Young
Ra, Yonsei University College of Medicine, Republic of Korea.
Hepatocytes were harvested from 6- to 8-week-old male C57BL/6 mice
using in situ collagenase perfusion, as described (West et al., 1989). All cells
were cultured at 37C in an atmosphere containing 5% CO2.
Cancer Cell Invasion Assay
To evaluate invasive activity, we used a modified transwell invasion assay
(Youngs et al., 1997). Using 24-transwell plates (Corning, Corning, NY, USA),
the inserts containing filters with pore size 8 mm were coated with collagen
type I (45 mg/30 ml/well) for invasion assay. Briefly, 2 3 104/well CAFs were
seeded in the lower well chambers for inducing cancer cell invasion. After
24 hr, 2 3 104/well OSCC cells were placed in the upper transwell chambers1588 Chemistry & Biology 18, 1581–1590, December 23, 2011 ª2011with porous filters. The cancer cells that penetrated the filter were fixed and
stained with 0.25% crystal violet. Cell invasion was quantified by counting
the invaded cells, which were counted in five separate microscopic fields
(1003) per filter, and the mean values per filter (±SD) were calculated from
three replicate filters.
Measurement of Cell Proliferation
Cell proliferation was measured using the MTT assay, as previously described
(Mosmann, 1983). Briefly, cells were seeded in a 96-well culture plate, 16 hr
before addition of the drug. MTT absorbance was read at 540 nm using
a microplate reader (VersaMax, BioRad, Hercules, CA, USA).
Chemical Library Screening
A tagged chemical library of 1040 benzoyl-capped triazines (Kim and Chang,
2007) was used for screening. CAFs were seeded in the lower chamber of
a transwell at a density of 2 3 104 cells/well. After overnight incubation, the
cell culture medium was changed to a serum-free medium and 5 mM of each
compound was added to the lower chamber. YD10B OSCC cells (2 3 104)
were then added to the upper, collagen-coated chamber (Figure 1A). After
48 hr incubation, OSCC invasion was measured by staining with 0.25%
crystal violet and cell counting. Cytotoxicity of S06 against YD10B cells
or CAFs in the coculture system was assessed by MTT assay, employing
transwells equipped with a filter of pore size 0.4 mm, which blocked cell
penetration through the filter, although co-cultured cells could still influence
each other.
Cytokine Antibody Array Analysis
The sandwich ELISA human cytokine antibody array was purchased from
RayBiotech (Norcross, GA, USA). CAF cells (2 3 105) were cultured in
T25 cm2 tissue culture flasks overnight and the medium was changed to
serum-free DMEM/F12 (3:1) medium with DMSO (vehicle) or 5 mM S06 after
three washes with PBS. After 24 hr incubation, the supernatants were
collected and examined according to the manufacturer’s instructions.
Enzyme-Linked Immunosorbent Assay
CCL7/MCP-3 and IL-8/CXCL8 in cell culture supernatants were quantified
by sandwich ELISA, using kits purchased from R&D Systems (Minneapolis,
MN, USA).
Isolation and Identification of Cellular Targets
Proteins were extracted from YD10B OSCC cells or CAFs by incubation with
extraction buffer (1 mM CaCl2, 150 mM NaCl, 10 mM Tris, pH 7.4, 1% Triton
X-100, and 1 mM PMSF plus one tablet of protease inhibitor cocktail (Roche,
Basel, Switzerland) per 10 ml buffer) for 5 min on ice. Crude lysate was centri-
fuged at 10,000 rpm for 10 min. The protein concentration of the supernatant
was measured by Bradford assay (Bio-Rad, Hercules, CA, USA) and adjusted
to a final concentration of 1 mg/ml prior to affinity chromatography. Twenty-five
ml of agarose affinity matrix conjugated compound was washed with 1ml bead
buffer (10mMTris, pH 7.4, 5mMNaF, 250mMNaCl, 5mMEDTA, 5mMEGTA,
and 0.1% Triton X-100 plus one tablet of protease inhibitor cocktail per 10 ml
buffer). Matrices were incubated with 100 ml of 200 mg protein extract plus
an identical volume of bead buffer at room temperature. For studies of compe-
tition drug binding to a cellular target, the competitor was added to the mixture
of protein extract/bead buffer and incubated at room temperature for
3060 min prior to incubation with the matrix. The supernatant containing
unbound proteins was removed by centrifugation and the matrices were
washed seven times with 1 ml bead buffer. Proteins bound to the matrices
were eluted by incubation with 80 ml 23 Laemmli buffer (Bio-Rad) at 95C
for 3 min. Eluted proteins were separated by 10% SDS-PAGE and visualized
by silver staining kit (GE Healthcare, St. Giles, UK). Prominent protein bands
specific to active matrices were excised from each gel and identified by
MALDI-TOF mass spectrometry (Korea Research Institute of Standards and
Science, Daejeon, Republic of Korea).
Western Blot Analysis
Proteins were harvested and separated by 8%–12.5% SDS-PAGE and
transferred onto 0.45 mm polyvinylidene fluoride (Pall, Port Washington, NY,Elsevier Ltd All rights reserved
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Tokyo, Japan).
Expression and Purification of Recombinant Proteins
The full length (1–732), N-terminal domain (12–230), or C-terminal domain
(539–732) of the human Hsp90a tagged with histidine was expressed in
Escherichia coli BL21. These proteins were purified using a previously
described method (Tropea et al., 2009). Ni-NTA-agarose beads (QIAGEN,
Venlo, Netherlands) were used for purification. Eluted protein concentrations
were determined using the Bio-Rad protein assay kit.
siRNA-Mediated Gene Silencing
Hsp90 and control siRNAs were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). CAFs were seeded in six-well plates at a cell density
of 13 105 cells/well. CAFs were transfected with 80 pmol of siRNA 24 hr after
seeding, following the manufacturer’s protocol. CAFs were used for experi-
ments 48 hr after transfection. Invasion assay and CCL7-ELISA were per-
formed after 24 hr co-culture of the siRNA-treated CAFs (2 3 104 cells/well)
and YD-10B (2 3 104 cells/well) in the 24-transwell system.
Zebrafish Study of Tumor Cell Metastasis
Wild-type AB zebrafish embryos were obtained using standard mating condi-
tions and staged for cell transplantation at 48 hpf. Embryos were dechorion-
ized using microforceps, anesthetized with tricaine and positioned on their
right side on a wet 1.0% agarose pad. YD10B OSCC cells were detached
from culture dishes using 0.05% trypsin-EDTA and washed twice with
PBS at room temperature. Cells were stained in 2 mg/ml 1,10-dioctadecyl-
3,3,30,30-tetramethyl-indocarbocyanine perchlorate (DiI) (Invitrogen, Carlsbad,
CA, USA) diluted in PBS and washed with FBS, followed by two washes
with PBS and one wash with 10% FBS diluted in PBS. Cells were kept on
ice before injection. Approximately 100 tumor cells suspended in 10% FBS
were injected into the center of the yolk sac using an injector (PV820 Pneu-
matic Picopump, World Precision Instruments, Sarasota, FL, USA) equipped
with borosilicate glass capillaries. Injected embryos were transferred to
a 96-well plate (1 embryo/well) containing the drug of interest diluted in
200 ml E3 media (without methylene blue) and maintained at 31C. Fifteen
embryos were used for each drug treatment group. Embryos were imaged
at 4 days post injection (dpi) using an upright fluorescent microscope (Leica,
Wetzlar, Germany). Occurrence of cancer cell migration was classified as
1003 microscopic observation of more than five microtumor foci that were
distinct from the injection site. Care and treatment of animals were conducted
in accordance with guidelines established by the Animal Care and Ethics
Committees of the Gwangju Institute of Science and Technology (GIST).
Statistical Analysis
Data were analyzed with the SPSS statistical program (version 17.0). One-way
ANOVA was used for comparison between multiple groups. Student’s t test
was used for comparison between two groups. P values of <0.05 were consid-
ered significant. Unless otherwise stated, data presented are representative of
three independent experiments.SUPPLEMENTAL INFORMATION
Supplemental information includes six figures and Supplemental Experimental
Procedures and can be foundwith this article online at doi:10.1016/j.chembiol.
2011.10.001.
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